Literature DB >> 26392494

Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.

Ryan K Shields1, M Hong Nguyen2, Ellen G Press3, Richard Cumbie4, Eileen Driscoll4, A William Pasculle4, Cornelius J Clancy5.   

Abstract

Precise FKS mutation rates among Candida species are undefined because studies have not systematically screened consecutive, disease-causing isolates. The Sensititre YeastOne (SYO) assay measures echinocandin MICs against Candida with less variability than reference broth microdilution methods. However, clinical breakpoint MICs may overstate caspofungin nonsusceptibility compared to other agents. Our objectives were to determine Candida FKS mutation rates by studying consecutive bloodstream isolates and to determine if discrepant susceptibility results were associated with FKS mutations. FKS hot spots were sequenced in echinocandin-intermediate and -resistant isolates and those from patients with breakthrough candidemia or ≥ 3 days of prior echinocandin exposure. Overall, 453 isolates from 384 patients underwent susceptibility testing; 16% were echinocandin intermediate or resistant. Intermediate susceptibility rates were higher for Candida glabrata than for other species (P < 0.0001) and higher for caspofungin than for other agents (P < 0.0001). Resistance rates were similar between agents. FKS mutations were detected in 5% of sequenced isolates and 2% of isolates overall. Corresponding rates among C. glabrata isolates were 8% and 4%, respectively. Among Candida albicans isolates, rates were 5% and <1%, respectively. Mutations occurred exclusively with prior echinocandin exposure and were not detected in other species. Isolates with discrepant susceptibility results did not harbor FKS mutations. Mutation rates among isolates resistant to ≥ 2, 1, and 0 agents were 75%, 13%, and 0%, respectively. In conclusion, FKS mutations were uncommon among non-C. glabrata species, even with prior echinocandin exposure. Discrepancies in echinocandin susceptibility by SYO testing were not driven by mutations and likely reflect imprecise caspofungin clinical breakpoints.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26392494      PMCID: PMC4649226          DOI: 10.1128/AAC.01973-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Authors:  M A Pfaller; M Castanheira; S R Lockhart; A M Ahlquist; S A Messer; R N Jones
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

Review 2.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

3.  EUCAST technical note on anidulafungin.

Authors:  M C Arendrup; J-L Rodriguez-Tudela; C Lass-Flörl; M Cuenca-Estrella; J P Donnelly; W Hope
Journal:  Clin Microbiol Infect       Date:  2011-09-16       Impact factor: 8.067

4.  Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.

Authors:  Mariana Castanheira; Leah N Woosley; Daniel J Diekema; Shawn A Messer; Ronald N Jones; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

Review 5.  Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia.

Authors:  Gregory A Eschenauer; Minh-Hong Nguyen; Cornelius J Clancy
Journal:  Ann Pharmacother       Date:  2015-06-23       Impact factor: 3.154

6.  Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.

Authors:  David R Andes; Nasia Safdar; John W Baddley; Geoffrey Playford; Annette C Reboli; John H Rex; Jack D Sobel; Peter G Pappas; Bart Jan Kullberg
Journal:  Clin Infect Dis       Date:  2012-03-12       Impact factor: 9.079

7.  Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.

Authors:  Nicholas Kartsonis; John Killar; Lori Mixson; Chao-Min Hoe; Carole Sable; Kenneth Bartizal; Mary Motyl
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

8.  Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.

Authors:  Maiken Cavling Arendrup; David S Perlin; Rasmus Hare Jensen; Susan Julie Howard; Joanne Goodwin; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

9.  Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method.

Authors:  A Espinel-Ingroff; M Alvarez-Fernandez; E Cantón; P L Carver; S C-A Chen; G Eschenauer; D L Getsinger; G M Gonzalez; N P Govender; A Grancini; K E Hanson; S E Kidd; K Klinker; C J Kubin; J V Kus; S R Lockhart; J Meletiadis; A J Morris; T Pelaez; G Quindós; M Rodriguez-Iglesias; F Sánchez-Reus; S Shoham; N L Wengenack; N Borrell Solé; J Echeverria; J Esperalba; E Gómez-G de la Pedrosa; I García García; M J Linares; F Marco; P Merino; J Pemán; L Pérez Del Molino; E Roselló Mayans; C Rubio Calvo; M Ruiz Pérez de Pipaon; G Yagüe; G Garcia-Effron; J Guinea; D S Perlin; M Sanguinetti; R Shields; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

10.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

View more
  21 in total

1.  Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for FKS-Associated Echinocandin Resistance in Candida glabrata Septic Arthritis and Osteomyelitis.

Authors:  William F Wright; Nika Bejou; Ryan K Shields; Kieren Marr; Todd P McCarty; Peter G Pappas
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Candidemia in Adults at a Tertiary Hospital in China: Clinical Characteristics, Species Distribution, Resistance, and Outcomes.

Authors:  Shaoming Lin; Ruilan Chen; Song Zhu; Huijun Wang; Lianfang Wang; Jian Zou; Jingdong Yan; Xiangdong Zhang; Dimitrios Farmakiotis; Xiaojiang Tan; Eleftherios Mylonakis
Journal:  Mycopathologia       Date:  2018-03-23       Impact factor: 2.574

3.  Tolerance to Caspofungin in Candida albicans Is Associated with at Least Three Distinctive Mechanisms That Govern Expression of FKS Genes and Cell Wall Remodeling.

Authors:  Feng Yang; Lulu Zhang; Hironao Wakabayashi; Jason Myers; Yuanying Jiang; Yongbing Cao; Cristina Jimenez-Ortigosa; David S Perlin; Elena Rustchenko
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 4.  Sphingolipids as targets for treatment of fungal infections.

Authors:  Rodrigo Rollin-Pinheiro; Ashutosh Singh; Eliana Barreto-Bergter; Maurizio Del Poeta
Journal:  Future Med Chem       Date:  2016-08-09       Impact factor: 3.808

Review 5.  Clinical perspectives on echinocandin resistance among Candida species.

Authors:  Ryan K Shields; M Hong Nguyen; Cornelius J Clancy
Journal:  Curr Opin Infect Dis       Date:  2015-12       Impact factor: 4.915

6.  Spontaneous Mutational Frequency and FKS Mutation Rates Vary by Echinocandin Agent against Candida glabrata.

Authors:  Ryan K Shields; Ellen G Kline; Kelley R Healey; Milena Kordalewska; David S Perlin; M Hong Nguyen; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

7.  Antifungal Susceptibility Testing Identifies the Abdominal Cavity as a Source of Candida glabrata-Resistant Isolates.

Authors:  Pilar Escribano; Jesús Guinea; Judith Díaz-García; Aina Mesquida; Ana Gómez; Marina Machado; Pablo Martín-Rabadán; Luis Alcalá; Carlos Sánchez-Carrillo; Elena Reigadas; Teresa Vicente; Patricia Muñoz
Journal:  Antimicrob Agents Chemother       Date:  2021-09-27       Impact factor: 5.191

8.  Fluconazole and Echinocandin Resistance of Candida glabrata Correlates Better with Antifungal Drug Exposure Rather than with MSH2 Mutator Genotype in a French Cohort of Patients Harboring Low Rates of Resistance.

Authors:  Sarah Dellière; Kelley Healey; Maud Gits-Muselli; Bastien Carrara; Alessandro Barbaro; Nicolas Guigue; Christophe Lecefel; Sophie Touratier; Marie Desnos-Ollivier; David S Perlin; Stéphane Bretagne; Alexandre Alanio
Journal:  Front Microbiol       Date:  2016-12-23       Impact factor: 5.640

Review 9.  Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?

Authors:  Vasiliki Soulountsi; Theodoros Schizodimos; Serafeim Chrysovalantis Kotoulas
Journal:  Infection       Date:  2021-06-16       Impact factor: 3.553

10.  Resistance to Echinocandins Complicates a Case of Candida albicans Bloodstream Infection: A Case Report.

Authors:  Laura Trovato; Dafne Bongiorno; Maddalena Calvo; Giuseppe Migliorisi; Albino Boraccino; Nicolò Musso; Salvatore Oliveri; Stefania Stefani; Guido Scalia
Journal:  J Fungi (Basel)       Date:  2021-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.